XBiotech Inc. (XBIT)
NASDAQ: XBIT
· Real-Time Price · USD
2.64
0.00 (0.00%)
At close: Oct 03, 2025, 3:59 PM
2.66
0.76%
After-hours: Oct 03, 2025, 07:50 PM EDT
Company Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus.
The company was incorporated in 2005 and is headquartered in Austin, Texas.
XBiotech Inc.
| Country | United States |
| IPO Date | Apr 15, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | John Simard |
Contact Details
Address: 5217 Winnebago Lane Austin, Texas United States | |
| Website | https://www.xbiotech.com |
Stock Details
| Ticker Symbol | XBIT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626878 |
| CUSIP Number | 98400H102 |
| ISIN Number | CA98400H1029 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Simard | Founder, President, Chief Executive Officer & Chairman |
| Angela Hu | Director of Finance |
| Dr. Sushma Shivaswamy Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2025 | 3 | Filing |
| Sep 30, 2025 | 3 | Filing |
| Sep 29, 2025 | 3 | Filing |
| Sep 16, 2025 | 3 | Filing |
| Sep 02, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Jul 07, 2025 | ARS | Filing |
| Jul 07, 2025 | DEF 14A | Filing |
| Jun 24, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |